Table 5.
A univariate analysis of the E-cadherin and vimentin expressions and clinicopathological features of PTC patients from the present case study (A) or from the TGCA database (B). In parentheses is the number of patients. TDS, Thyroid Differentiation Score.
| (A) | E-cadherin | p | Vimentin | p |
| Gender | ||||
| Male (n = 19) Female (n = 76) |
1.05 0.78 |
0.153 | 0.83 0.92 |
0.309 |
| Age (year) Corr. Coeff. | 0.022 | 0.835 | −0.173 | 0.096 |
| PTC histology | ||||
| Classical Variant (n = 72) Other Variants (n = 23) |
0.85 0.76 |
0.262 | 0.92 0.97 |
0.758 |
| BRAF | ||||
| Wild Type (n = 38) V600E (n = 38) |
0.84 0.94 |
0.905 | 0.90 0.92 |
0.767 |
| pT | ||||
| T1–2 (n = 39) T3–4 (n = 56) |
0.95 0.73 |
0.104 | 0.95 0.90 |
0.161 |
| pN | ||||
| N0 (n = 56) N1 (n = 39) |
0.80 0.81 |
0.256 | 0.92 0.90 |
0.478 |
| TNM Stage | ||||
| I–II (n = 60) III–IV (n = 35) |
0.80 0.81 |
0.814 | 0.92 0.90 |
0.274 |
| Recurrence | ||||
| No (n = 63) Yes (n = 16) |
0.94 0.73 |
0.102 | 0.90 0.84 |
0.282 |
| (B) | E-cadherin | p | Vimentin | p |
| Gender | ||||
| Male (n = 93) Female (n = 271) |
0.158 −0.074 |
0.625 | 0.092 −0.206 |
0.021 |
| Age (year) Corr. Coeff. | −0.065 | 0.216 | −0.165 | 0.002 |
| PTC histology | ||||
| Classical variant (n = 249) Follicular variant (n = 81) Tall cell variant (n = 28) |
0.074 −0.300 −0.177 |
0.012 | −0.150 −0.167 −0.318 |
0.203 |
| BRAF-like vs. RAS-like | ||||
| BRAF-like (n = 272) RAS-like (n = 116) |
−0.00005 −0.145 |
0.048 | −0.100 −0.241 |
0.028 |
| TDS | 0.029 | 0.564 | 0.008 | 0.871 |
| pT | ||||
| T1–2 (n = 231) T3–4 (n = 131) |
−0.029 −0.024 |
0.757 | −0.194 −0.091 |
0.260 |
| pN | ||||
| N0 (n = 172) N1 (n = 153) |
−0.025 −0.079 |
0.919 | −0.239 −0.044 |
0.021 |
| TNM Stage | ||||
| I–II (n = 250) III–IV (n = 112) |
0.065 −0.154 |
0.054 | −0.163 −0.149 |
0.667 |
| Recurrence | ||||
| No (n = 301) Yes (n = 22) |
−0.097 0.169 |
0.222 | −0.133 −0.297 |
0.539 |